Serrate RNA effector molecule homolog
Homo sapiens
当前结构中的状态
| Assembly | 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与共同组分 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|
| 1 | 蛋白同源多聚体 同源多聚体 蛋白 × 2 PDB 声明:dimeric(2) 与蛋白拷贝数一致 | 链 A; UniProt 171–270 链 B; UniProt 408–763 | 未记录 | 无其他共同聚合物 | X-RAY DIFFRACTION X-ray结晶条件:VAPOR DIFFUSION, SITTING DROP;pH 10.5;281 K;Protein solution at 6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8, mixed 1:1 with reservoir solution containing 1.2 M sodium dihydrogen phosphate, 0.8 M dipotassium hydrogen phosphate, 0.2 M lithium sulphate and 0.1 M CAPS pH 10.5. | 分辨率 3.22 Å R-free 0.322 |
数据库中的同蛋白其他状态
以下每一行都是同一 UniProt 蛋白在另一个 PDB 条目中的 biological assembly, “相对当前条目”直接指出证据层面的不同;没有差异标签表示当前已读取字段一致。
| 其他 PDB | 相对当前条目 6F7J | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法与环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 C
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 F
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 I
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 L
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 5 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 O
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 6 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 R
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 7 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 U
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 5OO6 Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide 提交 2017-08-06 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验环境不同 结构质量不同 | Assembly 8 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 X
827–871(45 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å R-free 0.268 |
| 6F7P Crystal structure of Human ARS2 residues 147-270 + 408-763 提交 2017-12-11 | 构建体不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 A
147–270(124 aa)
链 C
408–763(356 aa)
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7.8;281 K;Crystals were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution at 6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 0.2 M lithium sulphate and 20% (w/v) PEG 3550.
|
分辨率 3.70 Å R-free 0.309 |
| 6F7P Crystal structure of Human ARS2 residues 147-270 + 408-763 提交 2017-12-11 | 构建体不同 实验环境不同 结构质量不同 | Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 B
147–270(124 aa)
链 D
408–763(356 aa)
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7.8;281 K;Crystals were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution at 6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 0.2 M lithium sulphate and 20% (w/v) PEG 3550.
|
分辨率 3.70 Å R-free 0.309 |
| 6F7S Crystal structure of Human ARS2 residues 147-270 + 408-763 with deletion of loop B 提交 2017-12-11 | 构建体不同 突变/修饰不同 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 A
147–270(124 aa)
片段:UNP residues 147-270
链 C
408–567(160 aa)
片段:UNP residues 408-567,UNP residues 599-763
链 C
599–763(165 aa)
片段:UNP residues 408-567,UNP residues 599-763
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 8.3;281 K;Crystals of human ARS2 were obtained at 4 C in 2 microliter hanging drops with a 1:1 ratio of protein solution (6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine, pH 7.8) to crystallisation solution. The crystallisation solution was 0.2 M potassium citrate tribasic monohydrate, 20 % (w/v) PEG 3350.
|
分辨率 3.37 Å R-free 0.303 |
| 6F7S Crystal structure of Human ARS2 residues 147-270 + 408-763 with deletion of loop B 提交 2017-12-11 | 构建体不同 突变/修饰不同 实验环境不同 结构质量不同 | Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 B
147–270(124 aa)
片段:UNP residues 147-270
链 D
408–567(160 aa)
片段:UNP residues 408-567,UNP residues 599-763
链 D
599–763(165 aa)
片段:UNP residues 408-567,UNP residues 599-763
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 8.3;281 K;Crystals of human ARS2 were obtained at 4 C in 2 microliter hanging drops with a 1:1 ratio of protein solution (6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine, pH 7.8) to crystallisation solution. The crystallisation solution was 0.2 M potassium citrate tribasic monohydrate, 20 % (w/v) PEG 3350.
|
分辨率 3.37 Å R-free 0.303 |
| 6F8D Crystal structure of Human ARS2 residues 171-270 + 408-763 (P65 form) 提交 2017-12-13 | 实验环境不同 结构质量不同 | Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 A
171–270(100 aa)
链 C
408–763(356 aa)
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 10.5;277 K;Crystals of ARS2 were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution (6 mg/ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 1.2 M sodium dihydrogen phosphate, 0.8 M dipotassium hydrogen phosphate, 0.2 M lithium sulphate, 0.1 M CAPS pH 10.5
|
分辨率 3.48 Å R-free 0.292 |
| 6F8D Crystal structure of Human ARS2 residues 171-270 + 408-763 (P65 form) 提交 2017-12-13 | 实验环境不同 结构质量不同 | Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric |
链 B
171–270(100 aa)
链 D
408–763(356 aa)
|
未记录 | 未记录非水小分子 |
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 10.5;277 K;Crystals of ARS2 were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution (6 mg/ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 1.2 M sodium dihydrogen phosphate, 0.8 M dipotassium hydrogen phosphate, 0.2 M lithium sulphate, 0.1 M CAPS pH 10.5
|
分辨率 3.48 Å R-free 0.292 |
| 8PMP Structure of the human nuclear cap-binding complex bound to ARS2[147-871] and m7GTP 提交 2023-06-29 | 构建体不同 突变/修饰不同 聚集状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量不同 | Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric |
链 D
148–876(729 aa)
|
未记录 | MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1 |
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.43 Å |
共 5 个其他 PDB 条目、15 个 assembly。 打开独立比较页并筛选聚集状态
查看构建体与数据证据
| UniProt名称 | SRRT_HUMAN |
| Isoform | Q9BXP5-4 |
| PDB实体 | 1, 2 |
| 链与序列区间 | 作者链 A; PDB构建体 1–100; UniProt 171–270 作者链 B; PDB构建体 1–356; UniProt 408–763 |